Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

  • By

  • Katie Binley, PhD

  • May 1, 2026

  • 3 min

Share

Objective:

To develop dual-pathway gene therapies for retinal degenerative diseases, specifically targeting geographic atrophy (GA).

Key Findings:
  • Current single-pathway therapies for GA show modest effects and inconsistent improvements in visual function.
  • GA is multifactorial, necessitating simultaneous targeting of multiple pathways.
  • Neuroprotection is critical for achieving meaningful functional outcomes in GA treatment.
Interpretation:

The dual-pathway approach may overcome limitations of existing therapies by providing both anatomical and functional benefits.

Limitations:
  • The study does not provide extensive clinical trial data for IKAR-001.
  • Further research is needed to validate the long-term efficacy of the bicistronic platform.
Conclusion:

Ikarovec's gene therapy represents a promising next-generation treatment for GA and potentially other retinal diseases.

Original Source(s)

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

  • by Katie Binley, PhD

  • May 1, 2026

Related Content

The Retina’s Hidden Polarization Patterns

How structured light could reveal a new window into retinal function

  • September 2, 2026

  • 3 min
Reflections on Lumenis Accelerate from Laura Periman, MD

Optometric Management caught up with Laura Periman, MD, at the Lumenis Accelerate Owner’s Summit in Chicago on August 28 to discuss what attendees could take away from the event, both in clinical pearls and workflows and in practice management lessons.

  • September 1, 2026

  • 4 min
Rising Stars of Retina

Nominated by Power List alumni, this year's cohort of names to watch and celebrate are making waves in the retina field

  • September 8, 2026

  • 1 min